I-Mab (IMAB) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for I-Mab in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMAB shares.
View IMAB analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 12-month price objectives for I-Mab's shares. Their IMAB share price forecasts range from $24.00 to $25.00. On average, they expect the company's stock price to reach $24.67 in the next year. This suggests a possible upside of 647.5% from the stock's current price.
View analysts price targets for IMAB or view top-rated stocks among Wall Street analysts.

I-Mab's stock was trading at $4.18 at the beginning of 2023. Since then, IMAB stock has decreased by 21.1% and is now trading at $3.30.
View the best growth stocks for 2023 here.

I-Mab saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 1,640,000 shares, a drop of 13.7% from the April 30th total of 1,900,000 shares. Based on an average daily volume of 348,300 shares, the short-interest ratio is currently 4.7 days.
View I-Mab's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 28th 2023.
View our IMAB earnings forecast.

ETFs with the largest weight of I-Mab (NASDAQ:IMAB) stock in their portfolio include Loncar China Biopharma ETF (CHNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ETFMG Treatments Testing and Advancements ETF (GERM), Invesco Nasdaq Future Gen 200 ETF (QQQS), ALPS Medical Breakthroughs ETF (SBIO), iShares MSCI China Small-Cap ETF (ECNS), Invesco Golden Dragon China ETF (PGJ) and

Based on aggregate information from My MarketBeat watchlists, some companies that other I-Mab investors own include Inovio Pharmaceuticals (INO), Moderna (MRNA), ServiceNow (NOW), Novavax (NVAX), Gilead Sciences (GILD), Cisco Systems (CSCO), Enterprise Products Partners (EPD), G1 Therapeutics (GTHX), Intel (INTC) and Johnson & Johnson (JNJ).

(IMAB) raised $100 million in an initial public offering on Thursday, January 16th 2020. The company issued 7,400,000 shares at $12.00-$15.00 per share. Jefferies and CICC served as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers.

I-Mab trades on the NASDAQ under the ticker symbol "IMAB."

I-Mab's stock is owned by a variety of retail and institutional investors. Top institutional investors include Hhlr Advisors LTD. (8.37%), BlackRock Inc. (2.34%), Bank of America Corp DE (0.82%), JPMorgan Chase & Co. (0.67%), UBS Group AG (0.64%) and State Street Corp (0.63%).

Shares of IMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IMAB stock can currently be purchased for approximately $3.30.

I-Mab (NASDAQ:IMAB) has a market capitalization of $274.23 million and generates $13.81 million in revenue each year.

The company employs 228 workers across the globe.

I-Mab's mailing address is SUITE 802 WEST TOWER OMNLVISION 88 SHANGKE ROAD PUDONG DISTRICT, SHANGHAI F4, 201210. The official website for the company is www.i-mabbiopharma.com. The company can be reached via phone at 86-21-6057-8000 or via email at ir@i-mabbiopharma.com.